Caplin Point Laboratories Shares in Focus; Announces Completion of Unannounced US FDA Inspection at Facility

Caplin Point Laboratories has concluded an unannounced USFDA inspection at the Gummidipoondi facility of its subsidiary, Caplin Steriles Limited. The inspection pertained to the facility's injectable and ophthalmic manufacturing operations, as per the exchange filings. 

The inspection was conducted between August 13, 2026, and August 21, 2026. 

Inspection Completed at Caplin Steriles 

Caplin Steriles' Gummidipoondi facility is part of the company's injectable and ophthalmic business. The latest filing confirms that the inspection has now concluded, with the company stating that it will address the matters arising from the inspection and respond within the stipulated timeframe. 

About Caplin Point Laboratories 

Caplin Point Laboratories is a pharmaceutical company with a presence across Latin America, Francophone Africa, US and Europe. Its business includes finished formulations, APIs, clinical research and pharmaceutical distribution, with more than 4,000 product registrations across global markets. 

The company's US business focuses on injectable and ophthalmic products. Its website states that this business began in 2018 and accounted for 21% of revenue in FY26. 

Read More: Smartworks Coworking Spaces Share Price in Focus; Announces ₹235 Crore in Incremental Contracted Rental Revenue! 

Caplin Point Laboratories Share Price Performance  

As of 24 August 2026, at 12:40 PM, Caplin Point Laboratories share price is trading at ₹2,500.80 per share, reflecting a decline of 2.35% from the previous trading session. 

Conclusion 

Caplin Point Laboratories has completed the inspection at its Gummidipoondi facility following the August 13 to August 21 inspection period. The company has said it will respond within the stipulated timeframe. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.